Ikarian Capital’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.3M | Hold |
75,000
| – | – | 0.25% | 50 |
|
|
2025
Q1 | $1.64M | Buy |
75,000
+71,406
| +1,987% | +$1.56M | 0.2% | 46 |
|
|
2024
Q4 | $115K | Buy |
+3,594
| New | +$115K | 0.02% | 108 |
|
|
2024
Q3 | – | Hold |
0
| – | – | – | 102 |
|
|
2024
Q2 | – | Sell |
-35,092
| Closed | -$2.06M | – | 88 |
|
|
2024
Q1 | $2.06M | Buy |
35,092
+731
| +2% | +$43K | 0.23% | 43 |
|
|
2023
Q4 | $2.06M | Buy |
+34,361
| New | +$2.06M | 0.19% | 38 |
|
|
2023
Q3 | – | Sell |
-133,800
| Closed | -$12.2M | – | 85 |
|
|
2023
Q2 | $12.2M | Buy |
133,800
+33,800
| +34% | +$3.08M | 1.94% | 2 |
|
|
2023
Q1 | $6.6M | Buy |
+100,000
| New | +$6.6M | 1.5% | 10 |
|
|
2022
Q3 | – | Sell |
-41,900
| Closed | -$1.89M | – | 70 |
|
|
2022
Q2 | $1.89M | Buy |
+41,900
| New | +$1.89M | 0.35% | 30 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 158 |
|
|
2021
Q4 | – | Sell |
-347,545
| Closed | -$11.5M | – | 152 |
|
|
2021
Q3 | $11.5M | Buy |
+347,545
| New | +$11.5M | 0.81% | 8 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 162 |
|
|
2020
Q4 | – | Sell |
-18,726
| Closed | -$565K | – | 140 |
|
|
2020
Q3 | $565K | Buy |
18,726
+16,600
| +781% | +$501K | 0.04% | 79 |
|
|
2020
Q2 | $69K | Sell |
2,126
-50,000
| -96% | -$1.62M | 0.01% | 81 |
|
|
2020
Q1 | $1.4M | Buy |
52,126
+52,073
| +98,251% | +$1.39M | 0.11% | 43 |
|
|
2019
Q4 | $2K | Buy |
+53
| New | +$2K | ﹤0.01% | 53 |
|